Literature DB >> 33773118

The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study.

Stephanie J Salyer1, Justin Maeda2, Senga Sembuche2, Yenew Kebede2, Akhona Tshangela2, Mohamed Moussif3, Chikwe Ihekweazu4, Natalie Mayet5, Ebba Abate6, Ahmed Ogwell Ouma2, John Nkengasong2.   

Abstract

BACKGROUND: Although the first wave of the COVID-19 pandemic progressed more slowly in Africa than the rest of the world, by December, 2020, the second wave appeared to be much more aggressive with many more cases. To date, the pandemic situation in all 55 African Union (AU) Member States has not been comprehensively reviewed. We aimed to evaluate reported COVID-19 epidemiology data to better understand the pandemic's progression in Africa.
METHODS: We did a cross-sectional analysis between Feb 14 and Dec 31, 2020, using COVID-19 epidemiological, testing, and mitigation strategy data reported by AU Member States to assess trends and identify the response and mitigation efforts at the country, regional, and continent levels. We did descriptive analyses on the variables of interest including cumulative and weekly incidence rates, case fatality ratios (CFRs), tests per case ratios, growth rates, and public health and social measures in place.
FINDINGS: As of Dec 31, 2020, African countries had reported 2 763 421 COVID-19 cases and 65 602 deaths, accounting for 3·4% of the 82 312 150 cases and 3·6% of the 1 798 994 deaths reported globally. Nine of the 55 countries accounted for more than 82·6% (2 283 613) of reported cases. 18 countries reported CFRs greater than the global CFR (2·2%). 17 countries reported test per case ratios less than the recommended ten to 30 tests per case ratio range. At the peak of the first wave in Africa in July, 2020, the mean daily number of new cases was 18 273. As of Dec 31, 2020, 40 (73%) countries had experienced or were experiencing their second wave of cases with the continent reporting a mean of 23 790 daily new cases for epidemiological week 53. 48 (96%) of 50 Member States had five or more stringent public health and social measures in place by April 15, 2020, but this number had decreased to 36 (72%) as of Dec 31, 2020, despite an increase in cases in the preceding month.
INTERPRETATION: Our analysis showed that the African continent had a more severe second wave of the COVID-19 pandemic than the first, and highlights the importance of examining multiple epidemiological variables down to the regional and country levels over time. These country-specific and regional results informed the implementation of continent-wide initiatives and supported equitable distribution of supplies and technical assistance. Monitoring and analysis of these data over time are essential for continued situational awareness, especially as Member States attempt to balance controlling COVID-19 transmission with ensuring stable economies and livelihoods. FUNDING: None.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33773118     DOI: 10.1016/S0140-6736(21)00632-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  92 in total

Review 1.  The emergence, genomic diversity and global spread of SARS-CoV-2.

Authors:  Juan Li; Shengjie Lai; George F Gao; Weifeng Shi
Journal:  Nature       Date:  2021-12-08       Impact factor: 49.962

2.  Africa: tackle HIV and COVID-19 together.

Authors:  Nokukhanya Msomi; Richard Lessells; Koleka Mlisana; Tulio de Oliveira
Journal:  Nature       Date:  2021-12       Impact factor: 49.962

3.  COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021-2022.

Authors:  Duncan Chanda; Jonas Z Hines; Megumi Itoh; Sombo Fwoloshi; Peter A Minchella; Khozya D Zyambo; Suilanji Sivile; Davies Kampamba; Bob Chirwa; Raphael Chanda; Katongo Mutengo; Mazinga F Kayembe; Webster Chewe; Peter Chipimo; Aggrey Mweemba; Simon Agolory; Lloyd B Mulenga
Journal:  Open Forum Infect Dis       Date:  2022-09-11       Impact factor: 4.423

4.  Spatial and spatio-temporal epidemiological approaches to inform COVID-19 surveillance and control: a review protocol.

Authors:  Julius Nyerere Odhiambo; Carrie B Dolan
Journal:  Syst Rev       Date:  2022-07-14

5.  A Geographical Analysis of the African COVID-19 Paradox: Putting the Poverty-as-a-Vaccine Hypothesis to the Test.

Authors:  Tolulope Osayomi; Richard Adeleke; Lawrence Enejeta Akpoterai; Opeyemi Caleb Fatayo; Joy Temitope Ayanda; Judah Moyin-Jesu; Abdullahi Isioye; Ayobami Abayomi Popoola
Journal:  Earth Syst Environ       Date:  2021-06-14

Review 6.  Systematic review of empirical studies comparing the effectiveness of non-pharmaceutical interventions against COVID-19.

Authors:  Alba Mendez-Brito; Charbel El Bcheraoui; Francisco Pozo-Martin
Journal:  J Infect       Date:  2021-06-20       Impact factor: 38.637

7.  A Citywide 'Virus Testing': Chinese Government's Response to Preventing and Controlling the Second Outbreak of SARS-CoV-2.

Authors:  Liting Zhou; Hans Nibshan Seesaghur; Nadeem Akhtar; Jason Boolakee; Cornelius B Pratt
Journal:  Front Public Health       Date:  2021-06-16

Review 8.  RAAS, ACE2 and COVID-19; a mechanistic review.

Authors:  Ahmed Elshafei; Emad Gamil Khidr; Ahmed A El-Husseiny; Maher H Gomaa
Journal:  Saudi J Biol Sci       Date:  2021-07-10       Impact factor: 4.219

9.  SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey.

Authors:  Mohamed Bailor Barrie; Sulaiman Lakoh; J Daniel Kelly; Joseph Sam Kanu; James Squire; Zikan Koroma; Silleh Bah; Osman Sankoh; Abdulai Brima; Rashid Ansumana; Sarah A Goldberg; Smit Chitre; Chidinma Osuagwu; Justin Maeda; Bernard Barekye; Tamuno-Wari Numbere; Mohammed Abdulaziz; Anthony Mounts; Curtis Blanton; Tushar Singh; Mohamed Samai; Mohamed A Vandi; Eugene T Richardson
Journal:  medRxiv       Date:  2021-07-05

10.  Participating in a vaccine trial for COVID-19 in Senegal: trust and information.

Authors:  V Ridde; M F Ba; I Gaye; A I Diallo; E Bonnet; A Faye
Journal:  Hum Vaccin Immunother       Date:  2021-07-19       Impact factor: 4.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.